Cyclerion Therapeutics Stock Fundamentals
| CYCN Stock | USD 1.97 0.60 23.35% |
Cyclerion Therapeutics fundamentals help investors to digest information that contributes to Cyclerion Therapeutics' financial success or failures. It also enables traders to predict the movement of Cyclerion Stock. The fundamental analysis module provides a way to measure Cyclerion Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyclerion Therapeutics stock.
At this time, Cyclerion Therapeutics' Interest Expense is very stable compared to the past year. As of the 13th of November 2024, Selling General Administrative is likely to grow to about 16.2 M, while Total Revenue is likely to drop 0.00. Cyclerion | Select Account or Indicator |
Cyclerion Therapeutics Company Shares Outstanding Analysis
Cyclerion Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Cyclerion Therapeutics Shares Outstanding | 2.52 M |
Most of Cyclerion Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cyclerion Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cyclerion Shares Outstanding Historical Pattern
Today, most investors in Cyclerion Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cyclerion Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cyclerion Therapeutics shares outstanding as a starting point in their analysis.
Cyclerion Therapeutics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Cyclerion Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Cyclerion Therapeutics has 2.52 M of shares currently outstending. This is 98.61% lower than that of the Biotechnology sector and 97.65% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 99.56% higher than that of the company.
Cyclerion Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cyclerion Therapeutics's current stock value. Our valuation model uses many indicators to compare Cyclerion Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cyclerion Therapeutics competition to find correlations between indicators driving Cyclerion Therapeutics's intrinsic value. More Info.Cyclerion Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Cyclerion Therapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cyclerion Therapeutics' earnings, one of the primary drivers of an investment's value.Cyclerion Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclerion Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyclerion Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclerion Therapeutics by comparing valuation metrics of similar companies.Cyclerion Therapeutics is currently under evaluation in shares outstanding category among its peers.
Cyclerion Fundamentals
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.47 | ||||
| Current Valuation | 366.51 K | ||||
| Shares Outstanding | 2.52 M | ||||
| Shares Owned By Insiders | 21.90 % | ||||
| Shares Owned By Institutions | 40.69 % | ||||
| Number Of Shares Shorted | 14.44 K | ||||
| Price To Earning | (0.59) X | ||||
| Price To Book | 0.56 X | ||||
| Price To Sales | 55.50 X | ||||
| Gross Profit | (29.75 M) | ||||
| EBITDA | (9.65 M) | ||||
| Net Income | (5.26 M) | ||||
| Cash And Equivalents | 30.32 M | ||||
| Cash Per Share | 0.70 X | ||||
| Total Debt | 2.09 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 3.21 X | ||||
| Book Value Per Share | 3.49 X | ||||
| Cash Flow From Operations | (21.25 M) | ||||
| Short Ratio | 2.00 X | ||||
| Earnings Per Share | (3.29) X | ||||
| Target Price | 4.0 | ||||
| Beta | 1.92 | ||||
| Market Capitalization | 6.47 M | ||||
| Total Asset | 13.37 M | ||||
| Retained Earnings | (264.42 M) | ||||
| Working Capital | 5.94 M | ||||
| Current Asset | 109.19 M | ||||
| Current Liabilities | 18.4 M | ||||
| Net Asset | 13.37 M |
About Cyclerion Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyclerion Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclerion Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclerion Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 7.7 M | 7.9 M | |
| Cost Of Revenue | 74.8 K | 118.1 K | |
| Stock Based Compensation To Revenue | 18.95 | 19.89 | |
| Sales General And Administrative To Revenue | 43.95 | 46.15 | |
| Research And Ddevelopement To Revenue | 95.43 | 100.21 | |
| Revenue Per Share | 0.16 | 0.15 | |
| Ebit Per Revenue | (171.81) | (163.22) |
Pair Trading with Cyclerion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclerion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclerion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Cyclerion Stock
The ability to find closely correlated positions to Cyclerion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclerion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclerion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclerion Therapeutics to buy it.
The correlation of Cyclerion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclerion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclerion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclerion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Cyclerion Therapeutics Piotroski F Score and Cyclerion Therapeutics Altman Z Score analysis. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.29) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.47) | Return On Equity (1.50) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.